# Special Issue

# Vaccine Development for SARS-CoV-2 and Zoonotic Diseases

### Message from the Guest Editors

Modern reverse vaccinology techniques enable the development of a targeted adaptive immune response. Numerous vaccines against human infections have been created using the epitope prediction technique. This involves the creation of a possible vaccine candidate against "Plasmodium vivax" based on the epitope (AMA-1). Such methods have been used, for example, to combat the Ebola virus, Marburg virus, Crimean–Congo hemorrhagic fever virus, and Mokola Rabies virus, which are all human pathogenic viruses. These vaccines are developed using the proteomes of different pathogens. Hence, this demonstrates the capability of proteome-based vaccines and their role in containing diseases. Therefore, the current issue will focus on the development of different vaccines for different diseases using proteins. With these advancements, we welcome the submission of manuscripts on the following aspects:

- Protein-based vaccine design;
- Epitope platform development;
- Improving proteome-based vaccine prediction;
- Proteomics-based mRNA vaccine design;
- Identification and characterization of vaccine targets in the proteomes;
- Development and improvement of current peptide-based vaccines.

### Guest Editors

Dr. Abbas Khan
Prof. Dr. Dongqing Wei
Dr. Syed Shujait Ali

### Deadline for manuscript submissions

closed (15 August 2023)

**Vaccines**

**an Open Access Journal by MDPI**

**Impact Factor 3.4**
**CiteScore 7.7**
**Indexed in PubMed**

mdpi.com/si/150679

*Vaccines*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

# Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

# About the Journal

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

## Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI